Clinical trials: Recurrent Meningioma
Recurrent Meningioma, Grade I and Grade II
Ceritinib Treatment for Recurrent Meningiomas
In this study, patients with recurrent grade I and grade II meningiomas will receive a daily dose of ceritinib for abour two years. Patients will visit the clinic on average about every 2 months for assessments.
- Trial name
- CURE-M (NCT07893197)
- Testing
- Ceritinib
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Kevin Petrecca
Intracranial Meningioma, Recurrent Meningioma
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive).
- Conditions
- Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
- Trial name
- NCT02523014
- Testing
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib
- Where
- 784 sites in United States
- Volunteers
- 124 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Grade 1 Meningioma, Grade 2 Meningioma
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation…
- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Trial name
- NCT04082520
- Testing
- Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Residual, Progressive or Recurrent Grade II or III Meningioma
NEO100 and High-Grade Meningioma
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade…
- Trial name
- NCT05023018
- Testing
- NEO100
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Neonc Technologies, Inc.
Anaplastic (Malignant) Meningioma, Atypical Meningioma
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas.
- Conditions
- Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma
- Trial name
- NCT02847559
- Testing
- Bevacizumab, Electric Field Therapy, NovoTTF-200A Device
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Meningioma, Meningioma, Malignant
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back…
- Conditions
- Meningioma, Meningioma, Malignant, Recurrent Meningioma
- Trial name
- SRS-AIM (NCT06557512)
- Testing
- Hypofractionated Stereotactic Radiosurgery (SRS), Magnetic Resonance Imaging (MRI), Computed Tomography (CT)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Francisco
Grade 1 Meningioma, Grade 2 Meningioma
Comparing Radiation After Surgery to Observation After Surgery in Patients With Clinical Low-Risk, Molecular High-Risk Meningioma, and Evaluating Observation After Surgery in Patients With Clinical and Molecular Low-Risk Meningioma
This phase III trial compares post-surgical surveillance to post-surgical radiation therapy for improving survival without disease progression in clinically low-risk patients with a grade 1 meningioma that is new or that has come…
- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Recurrent Grade 1 Meningioma
- Trial name
- NCT07785687
- Testing
- Patient Observation, Magnetic Resonance Imaging, Biospecimen Collection
- Volunteers
- 464 people
- Sponsor
- NRG Oncology
Recurrent Meningioma
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come…
- Trial name
- NCT07150806
- Testing
- Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua Palmer
Grade 2 Meningioma, Grade 3 Meningioma
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
This phase I/II trial studies the side effects and best dose of nivolumab when given together with multi-fraction stereotactic radiosurgery and to see how well they work with or without ipilimumab in treating patients with grade…
- Conditions
- Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Trial name
- NCT03604978
- Testing
- Biospecimen Collection, Echocardiography Test, Ipilimumab
- Where
- 29 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Recurrent, Brain Tumor
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT04427384
- Testing
- GammaTile
- Where
- 54 sites in United States
- Volunteers
- 600 people
- Sponsor
- GT Medical Technologies, Inc.
High Grade Glioma, Meningioma
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET.
- Conditions
- High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma
- Trial name
- NCT05278208
- Testing
- LUTATHERA® (Lutetium Lu 177 dotatate)
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Nationwide Children's Hospital
Recurrent Meningioma
177Lu-DOTATATE for Recurrent Meningioma
Novel treatments are urgently needed for meningiomas progressing after local therapies (surgery, radiotherapy). So far, no effective systemic therapies are known in this situation.
- Trial name
- LUMEN-1 (NCT06326190)
- Testing
- Local standard of Care, 177Lu-DOTATATE
- Where
- 19 sites in Austria, France and 4 more
- Volunteers
- 136 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Grade I Meningioma, Adult, Grade II Meningioma, Adult
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
This phase II trial studies the effect of stereotactic radiosurgery and pembrolizumab in treating patients with meningioma that has come back (recurrent).
- Conditions
- Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult, Recurrent Meningioma
- Trial name
- NCT04659811
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Nancy Ann Oberheim Bush, MD
High Risk Meningioma, Recurrent Meningioma
68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma
The is phase 1 trial of 68Ga-Dotatate PET/MRI guided radiation dose escalation for high-risk meningiomas (defined as recurrent or subtotal resection of Grade 2, and any Grade 3 meningioma).
- Trial name
- NCT07353229
- Testing
- ⁶⁸Ga-Dotatate PET and MRI Guided Radiation Therapy, Magnetic Resonance Imaging (MRI), 68Ga-Dotatate PET Imaging
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Thomas Jefferson University
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.
Recurrent High Grade Meningioma
Trabectedin for Recurrent Grade II/III Meningioma
The aim of this study is to collect data on activity, toxicity and quality of life of trabectedin therapy in patients with recurrent high-grade meningioma.
- Trial name
- NCT02234050
- Testing
- Trabectedin, Local standard of care
- Where
- 47 sites in Austria, Belgium and 8 more
- Volunteers
- 90 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Glioma, High-grade Meningioma
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
This is an open label phase I clinical trial with two arms, representing single and fractionated radiation therapy (Figure 4.1). Within each arm the radiation dose is pre-determined and not escalated.
- Conditions
- Recurrent Glioma, High-grade Meningioma, Brain Metastasis
- Trial name
- NCT01324635
- Testing
- Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Recurrent or Progressive High Grade Meningioma
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma
This is a randomized, controlled, open-label, multicenter, Phase II clinical study designed to evaluate the efficacy and safety of SYHA1813 compared to investigators' choice in participants with recurrent or progressive…
- Trial name
- NCT06739213
- Testing
- SYHA1813, Investigator's Choice Treatment
- Volunteers
- 56 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd